ClinicalTrials.gg
CompletedNCT02048618Updated Feb 23, 2016

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

A Phase 2 interventional study of GLPG0634 and Placebo in Crohn's Disease, sponsored by Galapagos NV. Completed at 63 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-23.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Crohn Disease with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Crohn Disease · Russian Federation.

Enrollment
34th of 51
175 · median 310
Started
2014
the only one that year
Phase 2
15 of 54
none open now
Registered
15th of 54
by date
Lead sponsor
2 of 54
Galapagos NV

Among the 54 studies in Crohn Disease with a site in Russian Federation, this one is the 34th largest by enrollment of the 51 interventional ones that give a count, is the only one that started in 2014, is one of 15 in phase 2, and was the 15th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

2 of the 54 studies in Crohn Disease with a site in Russian Federation are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Crohn Disease with a site in Russian Federation, or all of them as a file.
02

Study summary

  • 180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition to their stable background treatment.
  • During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood and stool (Pharmacodynamics) will be determined. Also, the effects GLPG0634 administration on subjects' quality of life will be evaluated.
Read the detailed description
  • 180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated when taking GLPG0634 or matching placebo once daily in addition to their stable background treatment. The population will include 50% anti-TNF naïve patients and 50% of subjects previously exposed to anti-TNF.
  • The study will consist of 2 parts, with total treatment duration of 20 weeks. Randomisation in Part 1 will be stratified according to subject's previous anti-TNF exposure, C-reactive protein (CRP) level at Screening and oral corticosteroid use at Day -1. However, at Week 10, subjects will be re-randomized automatically and stratified according to the subject's clinical response (reduction of Crohn's Disease Activity Index (CDAI) of 100 points), previous anti-TNF exposure and corticosteroid use at Day -1 to receive GLPG0634 200 mg q.d., 100 mg q.d. doses, or matching placebo q.d. in a blinded fashion. In Part 2, all will continue the study until Week 20.
  • As efficacy parameters, the ability to achieve clinical response or remission, endoscopic response \& remission as well as mucosal healing with GLPG0634 given once daily compared to placebo will be evaluated after 10 weeks of treatment. In subjects who achieved clinical remission at Week 10, maintenance of the remission will be assessed during Part 2 of the study.
  • During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood and stool (Pharmacodynamics) will be determined. Also, the effects of different doses and dose regimens of GLPG0634 administration on subjects' quality of life will be evaluated.
03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Active Crohn's Disease
  • GLPG0634
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 75 years
  • Documented history of ileal, colonic, or ileocolonic CD
  • CDAI score ≥ 220 to ≤ 450
  • Evidence of active inflammation as demonstrated by endoscopic confirmation of active disease
  • Subjects previously not exposed to anti-TNF treatment (TNF-naïve) or subjects previously exposed to anti-TNF therapy at a registered dose, that has been discontinued at least 8 weeks prior to Screening and deemed by the treating physician as a primary or secondary non-responder or intolerant (TNF-experienced)
  • Continuation of concurrent treatment with oral (≤30 mg prednisolone eq/day), mesalazine, olsalazine, CD-related antibiotics and probiotics at stable dose is allowed
  • Previous exposure to immunomodulators is permitted, but must be discontinued
  • Haematology and biochemistry lab parameters within predefined ranges as stated in the protocol

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC
  • Stoma, gastric or ileoanal pouch, procto- or total colectomy, symptomatic stenosis or obstructive strictures, history of bowel perforation, (suspected) abscess; actively draining fistulae
  • Subject who has had surgical bowel resections within the past 6 months, short bowel syndrome or is receiving tube feeding, defined formula diets, or parenteral alimentation
  • Subject with positive Clostridium difficile toxin stool assay or evidence of any other gastrointestinal infection
  • Subject who has received non-permitted IBD therapies within specified timeframes, depending on the medication, as stated in the protocol
  • Subject with a (previous history of) dysplasia of the gastrointestinal tract
  • Concurrent gastro-intestinal or a history of cancer elsewhere
  • History of lymphoproliferative disease
  • Known active infection of any kind, current therapy for chronic infection or history of specific infections as stated in the protocol
  • Subject who is pregnant, lactating or not willing to maintain highly effective methods during the course of the study and 12 weeks thereafter
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    GLPG0634 200 mg QD

    2 tablets of 100 mg GLPG0634 in the morning

    Drug: GLPG0634

  • Experimental
    GLPG0634 100 mg QD

    1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning

    Drug: GLPG0634 · Drug: Placebo

  • Placebo comparator
    Placebo QD

    2 placebo tablets in the morning

    Drug: Placebo

Interventions

  • 100 mg oral tablet, intake once daily for 20 weeks

    Also known as: GLPG0634 tablets

  • DrugPlacebo

    placebo oral tablets, intake once daily for 20 weeks

    Also known as: Placebo tablets

06

What researchers measure

Primary outcomes

  1. Percentage of subjects achieving clinical remission at Week 10

    Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score \< 150 points

    Time frame: Week 10

Secondary outcomes

  1. Percentage of subjects achieving clinical remission

    Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score \< 150 points, assessed at every visit

    Time frame: Up to Week 20

  2. Percentage of subjects achieving clinical response

    Percentage of subjects achieving clinical response as defined by a decrease in Crohn's Disease Activity Index score of at least 100 points, assessed at every visit

    Time frame: Up to Week 20

  3. Percentage of subjects achieving endoscopic remission at Week 10

    Percentage of subjects achieving endoscopic remission as defined by a reduction of Simplified Endoscopy Score for Crohn's Disease (SES-CD) score ≤ 4, with ulcerated surface subscore no greater than 1 in any segment at Week 10

    Time frame: Week 10

  4. Percentage of subjects achieving endoscopic response at Week 10

    Percentage of subjects achieving endoscopic response as defined by a reduction of Simplified Endoscopy Score for Crohn's Disease (SES-CD) score by at least 50% from Screening at Week 10

    Time frame: Week 10

  5. Percentage of subjects achieving mucosal healing at Week 10

    Percentage of subjects achieving mucosal healing as defined by a Simplified Endoscopy Score for Crohn's Disease (SES-CD) score equal to 0 at Week 10

    Time frame: Week 10

  6. Change from Baseline in Crohn's Disease Activity Index score

    Change from Baseline in Crohn's Disease Activity Index score, assessed at every visit

    Time frame: Up to Week 20

  7. Change from Screening in endoscopic score

    Change from Screening in endoscopic Simplified Endoscopy Score for Crohn's Disease (SES-CD) score at Week 10

    Time frame: Week 10

  8. Change from Screening in histopathology biopsy score

    Change from Screening in histopathology biopsy score at Week 10

    Time frame: Week 10

  9. Change from Baseline in Subjects' Quality of Life (based on the Inflammatory Bowel Disease Questionnaire (IBDQ) questionnaire score)

    Change from Baseline in Subjects' Quality of Life based on the IBDQ questionnaire score at Week 10 and Week 20

    Time frame: Up to Week 20

  10. The number of subjects with adverse events

    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of adverse events (AEs)

    Time frame: From screening up to 2 weeks after last dose

  11. The number of subjects with abnormal lab tests

    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms laboratory test abnormalities

    Time frame: From screening up to 2 weeks after last dose

  12. The number of subjects with abnormal vital signs

    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of abnormalities in vital signs

    Time frame: From screening up to 2 weeks after last dose

  13. The number of subjects with abnormal ECG

    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of abnormalities in electrocardiogram (ECG)

    Time frame: From screening up to 2 weeks after last dose

  14. The plasma levels of GLPG0634 and its metabolite

    To characterize the pharmacokinetics (PK) of GLPG0634 and its metabolite by measuring the amount in plasma from Week 2 up to Week 20 at every visit

    Time frame: Up to Week 20

  15. The change versus Baseline in levels of immune- and inflammation-related parameters in whole blood and serum

    To characterize the pharmacodynamics (PD) of GLPG0634 and its metabolite by measuring the levels of immune- and inflammation-related parameters in whole blood and serum

    Time frame: Up to Week 20

  16. The change versus Baseline in levels of faecal calprotectin

    To characterize the pharmacodynamics (PD) of GLPG0634 and its metabolite by measuring the levels of faecal calprotectin

    Time frame: Up to Week 20

  17. The change versus Baseline in microbial communities in stool samples

    To characterize the effects of GLPG0634 and its metabolite on the microbial communities by measuring the levels of predominant microbiota in stool samples

    Time frame: Up to Week 10

07

Study locations

63 sites
  • St. Pierre University Hospital Center
    Brussels, Belgium
  • University Hospital Saint Luc
    Brussels, Belgium
  • University Hospital Ghent
    Ghent, Belgium
  • University Hospitals Leuven
    Leuven, Belgium
  • CHR de la Citadelle
    Liege, Belgium
  • Clinic Saint Joseph
    Liege, Belgium
  • Hepato-Gastroenterology HK Ltd.
    Hradec Kralove, Czech Republic
  • University Hospital Olomouc
    Olomouc, Czech Republic
  • Outpatient Clinic of Internal Medicine and Gastroenterology
    Pilsen, Czech Republic
  • Institute of Clinical and Experimental Medicine
    Prague, Czech Republic
  • Masaryk's Hospital Usti Nad Labem
    Usti nad Labem, Czech Republic
  • Hospital Znojmo
    Znojmo, Czech Republic
  • Hospital Gabriel Montpied
    Clermont-Ferrand, France
  • Beaujon Hospital
    Clichy, France
  • Dijon University Hospital Center
    Dijon, France
  • Hospital Michallon
    Grenoble, France
  • Lille Regional University Hospital Center
    Lille, France
  • North Hospital
    Marseille, France
  • Archet Hospital
    Nice, France
  • Saint Etienne University Hospital Center
    Saint Etienne, France
  • DRK Clinics Berlin Westend
    Berlin, Germany
  • Interdisciplinary Crohn Colitis Center Rhein Main
    Frankfurt-am-Main, Germany
  • Asklepios West Hospital Hamburg
    Hamburg, Germany
  • University Hospital Jena
    Jena, Germany
  • University Hospital Schleswig-Holstein
    Kiel, Germany
  • University Hospital Magdeburg
    Magdeburg, Germany
  • Gastroenterology Group Practice Minden
    Minden, Germany
  • Internal Medicine Group Practice Oldenburg
    Oldenburg, Germany
  • Drug Research Center Ltd.
    Balatonfured, Hungary
  • Clinexpert Medical Center
    Budapest, Hungary
  • Semmelweis University
    Budapest, Hungary
  • Szent Margit Hospital
    Budapest, Hungary
  • University of Debrecen, Medical and Health Science Center
    Debrecen, Hungary
  • Bekes County Pandy Kalman Hospital
    Gyula, Hungary
  • Tolna County Balassa Janos Hospital
    Szekszard, Hungary
  • Jan Biziel University Hospital #2
    Bydgoszcz, Poland
  • Saint Family Hospital Medical Center
    Lodz, Poland
  • H-T. Medical Center
    Tychy, Poland
  • Clinical Hospital of Ministry of Internal Affairs and Administration
    Warsaw, Poland
  • Maternal, Pediatric and Adolescent Healtcare Centre, Gastroenterology Diagnostic Facility for Adults
    Warsaw, Poland
  • Vivamed
    Warsaw, Poland
  • Active Health Center
    Wroclaw, Poland
  • Colentina Clinical Hospital
    Bucharest, Romania
  • Fundeni Clinical Institute
    Bucharest, Romania
  • Medical Center for Gastroenterology
    Cluj-Napoca, Romania
  • Center for Gastroenterology, Ltd
    Timisoara, Romania
  • Territorial Clinical Hospital
    Barnaul, Russian Federation
  • State Medical University
    Kazan, Russian Federation
  • Territorial Clinical Hospital
    Krasnoyarsk, Russian Federation
  • A.N. Ryzhikh State Research Center for Coloproctology
    Moscow, Russian Federation
  • City Clinical Hospital #24
    Moscow, Russian Federation
  • Moscow Clinical Research Center
    Moscow, Russian Federation
  • Vladimirsky Regional Clinical Research Institute
    Moscow, Russian Federation
  • Semashko Nizhny Novgorod Regional Clinical Hospital
    Nizhny Novgorod, Russian Federation
  • City Clinical Hospital #12
    Novosibirsk, Russian Federation
  • City Clinical Hospital #31
    Saint Petersburg, Russian Federation
  • First Pavlov State Medical University
    Saint Petersburg, Russian Federation
  • Mechnikov North-Western State Medical University
    Saint Petersburg, Russian Federation
  • St. Elizabeth City Hospital
    Saint Petersburg, Russian Federation
  • Queen Elizabeth Hospital
    Birmingham, United Kingdom
  • Royal Bournemouth Hospital
    Bournemouth, United Kingdom
  • St Mark's Hospital
    Harrow, United Kingdom
  • Manchester Royal Infirmary
    Manchester, United Kingdom
08

References and documents

Publications

  • Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017 Jan 21;389(10066):266-275. doi: 10.1016/S0140-6736(16)32537-5. Epub 2016 Dec 15. PubMed 27988142 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Nov 2015 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2014
First posted
Jan 29, 2014
Start
Feb 2014
Primary completionActual
Nov 2015
CompletionActual
Feb 2016
Last update
Feb 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02048618
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Jan 29, 2014
Start date
Feb 2014
Primary completion
Nov 2015
Completion
Feb 2016
Last update
Feb 23, 2016

Study contacts

Pille Harrison, MD
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion